Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, ...

A central Arkansas father is fighting for his life and hoping a stranger could be the answer to his prayers as he searches ...

A retrospective study of 86 patients with advanced urothelial carcinoma found that baseline kidney function, rather than ...

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)89% and 81% ...

The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc’s AZN Ultomiris ...

Met predefined primary and secondary objectives for the interim analysis CPV-104 was generally well tolerated in healthy volunteers and patients ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Vera Therapeutics (Nasdaq: VERA) announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in adults with primary IgA nephropathy (IgAN) met statistical ...

Sparsentan lowered blood pressure more than irbesartan at week 8, with mean differences of -7.2 mmHg systolic and -5.6 mmHg diastolic.

12-minute video also helped patients make treatment choices ...

AstraZeneca (NYSE: AZN) announced the US availability of Zegfrovy (sunvozertinib), a treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth ...